BIOCON NEWS why is Biocon Limited price falling or rising
BIOCON NEWS reasons for why stock price of Biocon Limited is falling or rising
BIOCON Biocon is falling or rising technical reasons
Technical analysis forecast of Biocon Stock is that its in a uptrend for shortterm, and I will avoid taking a SHORT or SELL trade in this stock. Look for opportunities to BUY or go LONG in Biocon BIOCON at this time. Stock is rising and might rise more.
It appears as if Biocon BIOCON gave a large move recently.
Stock of Biocon (BIOCON) is trading above an important moving average line, and it has been above this line for quite some time now. This is a good sign, and the stock might keep rising and move higher!
My analysis of Biocon is bullish for shortterm, but trade for tomorrow is selective. Take a BUY trade only if Biocon stays above 371.7, but if it comes below 371.7, then a intra day sell could be more profitable.
If you take a sell trade below 371.7, then use 371.7 as stoploss and 361.1 as target. However if you take a buy trade in Biocon, then use 371.7 as stoploss and 384.5 as target.
BIOCON Biocon is falling or rising NEWS fundamental reasons
Company Announcement Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on July 09, 2025. - NEWS as on 2025-07-10
Board Meeting to discuss Financial Results To consider and approve the financial results for the period ended Jun 30, 2025 - NEWS as on 2025-07-09
Company Announcement Biocon Limited has informed the Exchange about Schedule of meet - NEWS as on 2025-07-09
Biocon Biologics gets UK MHRA nod for biosimilars Vevzuo, Evfraxy Biocon Biologics Ltd has achieved a significant milestone. It has secured marketing authorizations in the UK for Vevzuo and Evfraxy. These are biosimilars of Denosumab. Vevzuo addresses skeletal events in adults with advanced malignancies. Evfraxy treats o - NEWS as on 2025-07-07 indiatimes.com
Company Announcement Biocon Limited has informed the Exchange about Copy of Newspaper Publication - NEWS as on 2025-07-04
Biocon biologics receives European Commission approval for Vevzuo, Evfraxy Denosumab biosimilars for bone diseases Biocon Ltd's arm, Biocon Biologics Ltd, has received European Commission authorisation for its Vevzuo and Evfraxy biosimilars, used to treat various bone diseases. Vevzuo addresses bone complications in cancer patients and giant cell tumors, while Evfraxy - NEWS as on 2025-07-03 indiatimes.com
Biocon eyes Canadian bonanza from generics of weight-loss 'super-drugs' Ozempic and Wegovy Biocon Ltd. is set to seek regulatory approvals for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting key markets like Canada, where patents expire next year. Managing Director Siddharth Mittal sees Canada as a prime opportunity, aiming for - NEWS as on 2025-07-02 indiatimes.com
Company Announcement Biocon Limited has informed the Exchange regarding a press release dated Jun 30, 2025, titled "Biocon Biologics Expands Insulin Access in Malaysia Over 100 Mn Cartridges of rh-Insulin Supplied to Health Ministry; 345,000+ patients served". - NEWS as on 2025-06-30
Company Announcement Biocon Limited has informed the Exchange about Agreements - NEWS as on 2025-06-27
Company Announcement - NEWS as on 2025-06-27
Company Announcement Biocon Limited has informed the Exchange about Communication to the shareholders w.r.t. TDS on Final Dividend - NEWS as on 2025-06-26
Company Announcement Biocon Limited has informed the Exchange regarding a press release dated Jun 24, 2025, titled "Biocon Biologics Collaborates with National Cancer Society Malaysia - NEWS as on 2025-06-24
Company Announcement Biocon Limited has informed the Exchange regarding a press release dated Jun 20, 2025, titled "Biocon Limited Concludes a Rs 4,500 Crore (USD 523 - NEWS as on 2025-06-23
Company Announcement Biocon Limited has informed the Exchange about Qualified Institutions Placement - Approval and adoption the Placement Document dated June 19, 2025 - NEWS as on 2025-06-20
Company Announcement Biocon Limited has informed the Exchange about Press Release - NEWS as on 2025-06-03
More announcements and NEWS
BIOCON Biocon Limited current price & indicator signals
Recent prices of BIOCON Biocon Limited are as follows: Daily volume is divided by 10 day averaged volume
| Date | Close | Range | Change % | Volume |
| 10 Thu Jul 2025 | 372.40 | 370.00 to 377.10 | -0.31% | 0.34 times |
| 09 Wed Jul 2025 | 373.55 | 369.00 to 379.35 | 1.14% | 0.75 times |
| 08 Tue Jul 2025 | 369.35 | 366.55 to 373.95 | -0.74% | 0.46 times |
| 07 Mon Jul 2025 | 372.10 | 371.45 to 382.00 | -2.09% | 0.6 times |
| 04 Fri Jul 2025 | 380.05 | 372.70 to 381.00 | 1.5% | 1.23 times |
| 03 Thu Jul 2025 | 374.45 | 367.10 to 376.30 | 1.6% | 1.06 times |
| 02 Wed Jul 2025 | 368.55 | 362.50 to 372.20 | 1.67% | 1.34 times |
| 01 Tue Jul 2025 | 362.50 | 354.00 to 363.45 | 1.91% | 0.96 times |
| 30 Mon Jun 2025 | 355.70 | 349.55 to 356.60 | 0.37% | 0.48 times |
| 27 Fri Jun 2025 | 354.40 | 350.00 to 355.55 | 1.11% | 0.83 times |
| 26 Thu Jun 2025 | 350.50 | 349.45 to 357.00 | -0.26% | 2.31 times |
| 25 Wed Jun 2025 | 351.40 | 343.05 to 355.45 | 0.63% | 2.54 times |
Videos related to: BIOCON NEWS why is Biocon Limited price falling or rising
Hindi Basics How To Trade In FnO Futures Options Stock Market
- NSE Screeners
- NSE Daily Screener
- NSE Weekly Screener
- NSE Monthly Screener
- Support & Resistance
- NSE Shares Near Support
- NSE Shares Near Resistance